Vaxxas Is A Biotechnology Company Based In Australiafounded In 2011 As A Spin Out From The University Of Queenslandthe Company Specializes In Needle Free Vaccine Delivery Systemsfocusing On Enhancing Vaccine Efficacy And Accessibility Through Its Proprietary High Density Microarray Patchhd Maptechnologythis Innovative Platform Uses A Small Patch With Thousands Of Microprojections To Deliver Vaccines Painlesslyand It Has Been Validated In Multiple Human Clinical Trials The Hd Map Technology Offers Several Advantagesincluding Thermostabilitywhich Reduces The Need For Refrigerationand Enhanced Immunogenicityleading To Improved Immune Responses Compared To Traditional Methodsvaxxas Is Advancing Clinical Programs For Various Infectious Diseases And Oncologywith Ongoing Phase I Trials For Multiple Candidatesthe Company Collaborates With Global Health Organizations And Pharmaceutical Leaders To Support Its Initiativesaiming To Launch The First Commercially Available Vaccine Patches To Improve Access In Resource Limited Regions
